N/A
N=7
Comparative Efficacy of Phenylbutyrate (PBA) vs. Benzoate in Urea Cycle Disorders
Urea Cycle Disorders, Inborn
Bottom Line
View on ClinicalTrials.gov: NCT02111200 ↗Enrolled (actual)
7
Serious AEs
0.0%
Results posted
Dec 2017
Primary outcome: Primary: Urinary Hippuric Acid — 16.4; 0; 10.5 mmol/24 hours
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Sodium Benzoate (Drug); Sodium Phenylbutyrate (Drug)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Baylor College of Medicine
- Primary completion
- Oct 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Urinary Hippuric Acid |
16.4; 0; 10.5 | — |
| PRIMARY Urinary PAGN Excretion |
0; 15.3; 9.3 | — |
| PRIMARY Total Nitrogen as a Conjugate of the Drug |
16.4; 29; 30.7 | — |
Summary
The investigators will study and compare how effectively sodium phenylbutyrate, sodium benzoate, and a combination of the two, help excrete nitrogen in healthy volunteers. Subject participation will require three, separate, four-day study periods at least one week apart. During one study period (also called a treatment arm), subjects will take sodium phenylbutyrate; during another they will take sodium benzoate; during another they will take a combination of the two medications.
We expect to find that phenylbutyrate is more effective at removing nitrogen than benzoate or a combination of the two.
Eligibility Criteria
Inclusion Criteria
- Healthy volunteers
Exclusion Criteria
- Subjects with (a) a history of frequent dietary protein intolerance, (b) a history of chronic or acute liver diseases which may result in altered hepatic synthetic capacity (e.g., hepatitis), (c) acute or chronic disease or on medications that in the opinion of the clinical investigators will interfere with the measurements (e.g., drugs which may have hepatotoxicity as potential side effects), (d) a physical disability that will interfere with their ability to either conform to the dietary regimes or undergo the isotopic infusions, (e) pregnancy or recent (<6 months)/current lactation, (f) intercurrent evidence of significant hyperammonemia (more than 100 µmol/L), (g) any clinical abnormality of Grade 3 or greater according to the Common Terminology Criteria for Adverse Events v.4.0 (CTCAE), (h) any condition(s) not covered by the CTCAE, or (i) a severe or life-threatening toxicity at screening, will be excluded from the study. Subjects taking ammonia scavenger medications will not be enrolled.
Data sourced from ClinicalTrials.gov (NCT02111200). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.